ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Otsuka Holdings Co., Ltd.

Business Summary

Otsuka Holdings Co., Ltd. engages in the manufacture and sale of pharmaceuticals and nutritional supplements. It operates through the following business segments: Pharmaceuticals, Nutraceuticals, Consumer Products, and Others. The Pharmaceuticals segment manufactures therapeutic drugs and infusions focusing on the central nervous system, oncology, and infectious diseases. The Nutraceuticals segment develops and markets nutrition products such as nutritional food, quasi-drugs, health drinks, and dietary supplements for homes, medical facilities, and nursing care units. The Consumer Products segment sells mineral water, food, and beverages. Its products include Bon Curry, Mannan Hikari, and ReSOLA. The Others segment distributes functional and fine chemicals, optical inspection devices, and clinical diagnosis equipment. The company was founded on July 8, 2008 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2019 JPYUSD
Revenue1,396.24B12,808.27M
Gross Profit944,943M8,668.34M
Operating income171,547M1,573.66M
Income before tax173,515M1,591.72M
Net income127,152M1,166.41M
EBITDA247,237M2,268.00M
Diluted EPS231.132.12
Dividends Per Share1000.91
Total Assets2,581.30B23,752.55M
Total liabilities785,863M7,231.31M
Total equity1,766.27B16,252.78M
Operating cash flow192,634M1,767.10M
Currency in JPYCurrency in USD

Historical Data

 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 1,427.37B 1,195.74B 1,239.95B 1,291.98B 1,396.24B
Gross Profit 974,909M 789,415M 817,540M 850,149M 944,943M
Operating income 135,762M 84,435M 112,679M 104,918M 171,547M
Income before tax 137,929M 100,706M 103,712M 109,497M 173,515M
Net income 101,957M 92,563M 112,492M 82,492M 127,152M
EBITDA 194,918M 144,009M 174,914M 164,193M 247,237M
Diluted EPS 188.15 170.70 206.99 151.26 231.13
Dividends Per Share 100 100 100 100 100
Total Assets 2,575.28B 2,478.29B 2,480.25B 2,476.63B 2,581.30B
Total liabilities 847,907M 739,845M 658,303M 744,366M 785,863M
Total equity 1,698.46B 1,710.53B 1,793.27B 1,704.50B 1,766.27B
Operating cash flow 257,892M 142,004M 102,832M 135,821M 192,634M
 Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019
Revenue 11,790.17M 11,004.58M 11,057.80M 11,698.18M 12,808.27M
Gross Profit 8,052.78M 7,265.07M 7,290.76M 7,697.63M 8,668.34M
Operating income 1,121.39M 777.06M 1,004.86M 949.97M 1,573.66M
Income before tax 1,139.29M 926.80M 924.89M 991.43M 1,591.72M
Net income 842.16M 851.86M 1,003.19M 746.92M 1,166.41M
EBITDA 1,610.03M 1,325.33M 1,559.87M 1,486.67M 2,268.00M
Diluted EPS 1.55 1.57 1.84 1.36 2.12
Dividends Per Share 0.82 0.92 0.89 0.90 0.91
Total Assets 21,408.03M 21,248.25M 22,017.36M 22,573.34M 23,752.55M
Total liabilities 7,048.56M 6,343.25M 5,843.79M 6,784.54M 7,231.31M
Total equity 14,119.15M 14,665.67M 15,919.02M 15,535.70M 16,252.78M
Operating cash flow 2,130.19M 1,306.87M 917.04M 1,229.78M 1,767.10M

Valuation Measures

Dec 2019
PER20.81
ROA5.02%
ROE7.32%
Operating margin12.28%
Profit margin9.10%

Key executives

  • President, CEO & Representative Director: Tatsuo Higuchi
  • Chief Financial Officer & Director: Yuko Makino
  • Vice President-Global Clinical Development: Frank Czerwiec
  • Director & Head-Business Portfolio Management: Shuichi Takagi
  • Head-Business Development & Planning: Kuniaki Natsume

Shareholders

  • OTSUKA FAMILY /OTSUKA HOLDINGS/ (15.8%)
  • Nomura Asset Management Co., Ltd. (4.4%)
  • Otsuka Holdings Co., Ltd. (2.7%)
  • Otsuka Holdings Employee Stock Ownership Plan (2.3%)
  • The Vanguard Group, Inc. (2.1%)
  • The Awa Bank Ltd. (1.9%)
  • Daiwa Asset Management Co. Ltd. (1.7%)
  • Nikko Asset Management Co., Ltd. (1.7%)
  • Alfresa Holdings Corp. (1.1%)
  • Norges Bank Investment Management (1.1%)

Contact Details

  • Website:http://www.otsuka.com
  • Address: Shinagawa Grand Central Tower, 12/F, 2-16-4 Konan, Tokyo, 108-8241, Japan
  • Phone: +81.3.6717.1410

Related Companies

  • Otsuka Europe Development & Commercialisation Ltd.
  • Otsuka Holdings Restricted Stock Compensation Plan
  • Otsuka Shanghai Research Institute
  • Otsuka Pharmaceutical (Switzerland) GmbH
  • Otsuka Pharmaceutical (HK) Ltd.
  • Otsuka America Foods, Inc.
  • Otsuka Pharma Scandinavia AB
  • Sichuan Otsuka Pharmaceutical Co. Ltd.
  • Otsuka (Shanghai) Foods-Safety Research & Development Co. Ltd.
  • Shanghai Otsuka Foods Co. Ltd.
  • Otsuka Pharmaceuticals (U.K.) Ltd.
  • Taiho Oncology, Inc.
  • Tianjin Otsuka Beverage Co., Ltd.
  • ReCor Medical, Inc.
  • Otsuka Medical Devices Co., Ltd.
  • Otsuka Holdingse Mployee Incentive Plan
  • Otsuka Holdings Employee Stock Ownership Plan
  • Otsuka Techno Corp.
  • Otsuka Foods Co. Ltd.
  • JIMRO Co., Ltd.
  • Nutrition & Sante' Italia SpA
  • Otsuka Pharma GmbH
  • Otsuka Packaging Ind Co. Ltd.
  • Nutrition & Sante SAS
  • Otsuka Pharmaceutical SA
  • Nardobel SAS
  • Euriso Top
  • Nutrition et Soja
  • Nutrition & Sante Iberia SL
  • JO Pharma KK

Competitors

  • JW Holdings Corporation
  • Kura Oncology, Inc.
  • Church & Dwight Co., Inc.
  • BridgeBio Pharma, Inc.
  • Intra-Cellular Therapies, Inc.
  • Deciphera Pharmaceuticals, Inc.
  • Oasmia Pharmaceutical AB
  • Supernus Pharmaceuticals, Inc.
  • BioLineRX Ltd.
  • VistaGen Therapeutics, Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Univo Pharmaceuticals Ltd.
  • Minerva Neurosciences Inc
  • Qurient Co., Ltd.
  • Rafael Holdings, Inc. Class B
  • Reata Pharmaceuticals, Inc. Class A
  • Vanda Pharmaceuticals Inc.
  • Alkermes Plc
  • SELLAS Life Sciences Group, Inc.
  • Axsome Therapeutics, Inc.
  • Aprea Therapeutics, Inc.
  • BioGaia AB Class B
  • ACADIA Pharmaceuticals Inc.
  • Exalenz Bioscience Ltd
  • Onconova Therapeutics Inc.
  • Adamas Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals, Inc.
  • Pieris Pharmaceuticals, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Aptinyx Inc
Last Updated on 6 Apr, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media